General health care issues related to the pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A)
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Duration: December 1, 2005
to
December 31, 2010
General Issues: Health Issues , Medicare/Medicaid , Pharmacy , Taxation/Internal Revenue Code , Government Issues
Spending: about $240,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2005: House of Representatives, U.S. Senate, Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2010
CAPITOL HILL CONSULTING GROUP terminated an engagement in which they represented ELI LILLY AND COMPANY on Jan. 19, 2011.
Original Filing: 300346499.xml
Lobbying Issues
General health care issues related to the pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on Oct. 14, 2010.
Original Filing: 300313183.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Follow On Biologics; health reform; America's Affordable Health Choices Act (H.R. 3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on July 14, 2010.
Original Filing: 300286821.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2010
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on April 19, 2010.
Original Filing: 300266515.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on Jan. 8, 2010.
Original Filing: 300228353.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (H.R.2184); Follow On Biologics; Health Reform; America's Affordable Health Choices Act (H.R.3200); America's Healthy Future Act; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on Oct. 7, 2009.
Original Filing: 300201573.xml
Lobbying Issues
general healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Follow-on Biologics; Comparative Effectiveness; Comparative Effectiveness Research Act (S.3408); Enhanced Health Care Value for All Act (HR2184); Promoting Innovation and Access to Life-saving Medicine Act (HR1427/S.726); Biologics Price Competition and Innovation Act of 2007 (S.1695); Pathway for Biosimilars Acr (HR1548); Health Reform; America's Affordable Health Choices Act (HR3200); America's Healthy Future Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (HR3200); America's Healthy Future Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on July 14, 2009.
Original Filing: 300176445.xml
Lobbying Issues
general healthcare issues related to pharmaceutical and biological products; Federal, Food Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Follow-on Biologics; Comparative Effectiveness: Comparative Effectiveness Reserach Act (S.3408); Enhanced Health Care Value for All Act (HR2184); Promoting Innovation and Access to Life-saving Medicine Act (HR1427/S.726); Biologics Price Competition and Innovation Act of 2007 (S.1695); Pathway for Biosimilars Act (HR1548); Health Reform; Affordable Health Choices Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
general Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on April 15, 2009.
Original Filing: 300149327.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); FDA Globalization Act (H.R. 759); Follow-on Biologics; Comparative Effectiveness: Comparative Effectiveness Research Ace (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Promoting Innovation and Access to Life-saving Medicine Act (H.R. 1427/S.726); Biologics Price Competition and Innovation Act (S.1695)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on Jan. 14, 2009.
Original Filing: 300117417.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9)
Public Health Service Act (42 USC 6A); Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251); Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380).Follow-on biologics: Access to Life-Saving Medicine Act (HR 1038); Patient Protection and Innovative Biologic Medicines Act (HR 1956); Biologics Price Competition and Innovation Act (S. 1695); Pathway for Biosimilars Act (HR 5629).
Comparative Effectiveness: Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (HR 2184).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement.
Physician gifts: Physician Payments Sunshine Act (S. 2029); Drug and Medical Device Company Gift Disclosure Act (HR 3023); False Claims Act Correction Act (HR 4854/S. 2041); Medicare Part D: Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173); Medicare Prescription Price Negotiation Act (HR 4/S. 3).Medicare Improvements for Patients and Providers Act (HR 6331); Supplemental Appropriations Act (HR 2642).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on Oct. 17, 2008.
Original Filing: 300096980.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9)
Public Health Service Act (42 USC 6A); Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251); Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380).Follow-on biologics: Access to Life-Saving Medicine Act (HR 1038); Patient Protection and Innovative Biologic Medicines Act (HR 1956); Biologics Price Competition and Innovation Act (S. 1695); Pathway for Biosimilars Act (HR 5629).
Comparative Effectiveness: Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (HR 2184).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement.
Physician gifts: Physician Payments Sunshine Act (S. 2029); Drug and Medical Device Company Gift Disclosure Act (HR 3023); False Claims Act Correction Act (HR 4854/S. 2041);
Medicare Part D: Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173); Medicare Prescription Price Negotiation Act (HR 4/S. 3).
Medicare Improvements for Patients and Providers Act (HR 6331); Supplemental Appropriations Act (HR 2642).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2008
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on July 9, 2008.
Original Filing: 300062095.xml
Lobbying Issues
General Healthcare Issues pertaining to Eli Lilly and Company, including but not limited to drug importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues pertaining to Eli Lilly and Company. including but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Pharmaceutical issues pertaining to Eli Lilly and Company, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatch-Waxman Act; and drug importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General tax issues pertaining to Eli Lilly and Company
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of ELI LILLY AND COMPANY in Q12008 on April 28, 2008.
Original Filing: 300057218.xml
Lobbying Issues
General healthcare issues pertaining to Eli Lilly and Company, including but not limited to, drug imporation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues pertaining to Eli Lilly Company, including but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Pharmaceutical issues pertaining to Eli Lilly Company, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatch-Waxman Act; and drug inportation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General tax issues pertaining to Eli Lilly and Company
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $20,000. The report was filed on April 16, 2008.
Original Filing: 300038603.xml
Lobbying Issues
General healthcare issues pertaining to Eli Lilly and Company, including but not limited to, drug imporation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues pertaining to Eli Lilly Company, including but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Pharmaceutical issues pertaining to Eli Lilly Company, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatch-Waxman Act; and drug inportation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General tax issues pertaining to Eli Lilly and Company
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives U.S. Senate
0th Quarter, 2007
In MM, CAPITOL HILL CONSULTING GROUP lobbied for ELI LILLY AND COMPANY , earning $40,000. The report was filed on Aug. 1, 2007.
Original Filing: 200043605.xml
Lobbying Issues
General healthcare issues pertaining to Eli Lilly and Company
Lobbying Issues
General medicare issues pretaining to Eli Lilly and Company.
Lobbying Issues
General pharmaceutical issues pertaining to Eli Lilly and Company.
Lobbying Issues
General tax issues pretaining to Eli Lilly and Company
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2005
Capitol Hill Consulting Group filed a lobbying registration on Feb. 1, 2006 to represent Eli Lilly and Company, effective Dec. 1, 2005.
Original Filing: 100005215.xml
Issue(s) they said they’d lobby about: General healthcare, medical care, pharmaceutical and tax issues .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate